Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
Reginelli
J P
JP
Topol
E J
EJ
D000077284:Abciximab; D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents; D020521:Stroke / Q000188:drug therapy*; D013577:Syndrome
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab